Clinical and Translational Science Center Scholarly Output


Kanwal Qidwai

Document Type


Publication Date



In 1974, FDA approved Methadone, an opioid agonist for Methadone Maintenance Therapy (MMT), a well-known rehabilitation program for opioid use disorder. Due to severe side effects of Methadone including withdrawal, relapse, respiratory depression, and death, FDA restricted MMT to be managed under the supervision of opioid licensed facility in inpatient settings. Opioid dependence due to chronic pain and subsequent addiction in US has increased enormously in the last two decades and has led to an emergent need of a flexible treatment method that has minimal side effects, is cost effective and can be prescribed in office-based settings. In 2002, FDA approved Buprenorphine, a partial opioid agonist, which meets the above-mentioned criteria (1). To demonstrate that Buprenorphine is a drug of choice for opioid addiction, I searched three relevant databases, PubMed, PsycINFO and Web of Knowledge. Based on inclusion and exclusion criteria, I narrowed my search from 149 to 35 articles, then selected 3 most relevant articles and validated them via number of times these articles were used as a reference (time cited) and retrieved 25 similar articles that are present in my reference list. These 25 articles validated that Buprenorphine is efficacious, easily accessible, has less side effects and can be used in pregnancy, HIV and neonate when compared to Methadone.

Language (ISO)



University of New Mexico Clinical and Translational Science Center (UNM CTSC)


Master of Science in Clinical Research (MSCR), University of New Mexico (UNM), Methadone; Buprenorphine; HIV Infection; Pregnancy; Hepatitis B Infection; Hepatitis C Infection; IV Drug abusers; Opioid Overdose; Neonatal Abstinence Syndrome; Respiratory Depression; Relapse; Hepatic Impairment; Renal Impairment; Maternal Opioid Treatment Experimental Research (MOTHER)


Final Paper for BMI Level One Course